Q32 Bio Secures $10.5M Financing with 1.67M Shares and 1.03M Warrants
Q32 Bio announced a $10.5M registered direct offering of 1,666,679 shares at $3.90 and pre-funded warrants for 1,025,654 shares at $3.8999 each, raising gross proceeds before expenses. Net proceeds will support research, clinical development and commercialization, including advancing bempikibart into Phase 2 trials for alopecia areata.
1. Registered Direct Offering Details
Q32 Bio entered into a definitive agreement to raise approximately $10.5 million through a registered direct offering led by a new institutional investor alongside an existing public institutional participant.
2. Share and Warrant Terms
The company issued 1,666,679 shares of common stock at $3.90 per share and pre-funded warrants to purchase 1,025,654 shares at $3.8999 each, exercisable immediately at a nominal $0.0001 exercise price.
3. Use of Proceeds
Net proceeds, together with existing cash and marketable securities, will fund working capital needs, research, clinical development and commercialization efforts, specifically supporting the advancement of bempikibart into future clinical trials for alopecia areata.
4. Offering Closing and Conditions
The offering is expected to close on or about February 18, 2026, pending satisfaction of customary closing conditions.